GSK plans appeal against US ruling
DRUGS firm GlaxoSmith- Kline (GSK) is to fight a judge's ruling that could dent sales of its leading product. Last year, the anti-depressant treatment Paxil recorded sales of £2.055bn worldwide, but its reign could be endangered after the US District